Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart and Anlotinib in Resectable Hepatocellular Carcinoma
NCT04888546Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of benmelstobart in hepatocellular carcinoma (HCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Pathological complete response rate at 6 months and Overall response rate at 6 months. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04888546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888546.